cyproheptadine has been researched along with Stroke in 2 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to examine how the administration and dosing of the anti-serotonergic medication cyproheptadine hydrochloride (HCl) affects involuntary muscle hypertonicity of the spastic and paretic hands of stroke survivors." | 9.51 | Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke. ( Bansal, N; Barry, A; Kamper, D; Roth, E; Seo, N; Stoykov, ME; Triandafilou, K; Vidakovic, L, 2022) |
| "The goal of this study was to examine how the administration and dosing of the anti-serotonergic medication cyproheptadine hydrochloride (HCl) affects involuntary muscle hypertonicity of the spastic and paretic hands of stroke survivors." | 5.51 | Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke. ( Bansal, N; Barry, A; Kamper, D; Roth, E; Seo, N; Stoykov, ME; Triandafilou, K; Vidakovic, L, 2022) |
| "This single-dose placebo-controlled study examined whether a serotonin receptor (5-HT2) antagonist, cyproheptadine hydrochloride, could reduce delay in muscle relaxation of a key paretic long finger flexor muscle immediately after grip for persons with stroke." | 3.77 | Effect of a serotonin antagonist on delay in grip muscle relaxation for persons with chronic hemiparetic stroke. ( Bogey, RA; Fischer, HW; Kamper, DG; Rymer, WZ; Seo, NJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamper, D | 1 |
| Barry, A | 1 |
| Bansal, N | 1 |
| Stoykov, ME | 1 |
| Triandafilou, K | 1 |
| Vidakovic, L | 1 |
| Seo, N | 1 |
| Roth, E | 1 |
| Seo, NJ | 1 |
| Fischer, HW | 1 |
| Bogey, RA | 1 |
| Rymer, WZ | 1 |
| Kamper, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Altering Activation Patterns in the Distal Upper Extremity After Stroke[NCT02418949] | 96 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)
| Intervention | Seconds (Mean) |
|---|---|
| Cyproheptadine + AMP | -1.66 |
| Placebo for Cyproheptadine + Stretching | -0.96 |
| Cyproheptadine + Stretching | -1.06 |
| Placebo for Cyproheptadine + AMP | -2.65 |
GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)
| Intervention | Seconds (Mean) |
|---|---|
| Cyproheptadine + AMP | -3.66 |
| Placebo for Cyproheptadine + Stretching | -0.51 |
| Cyproheptadine + Stretching | -4.00 |
| Placebo for Cyproheptadine + AMP | -3.89 |
1 trial available for cyproheptadine and Stroke
| Article | Year |
|---|---|
Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke.
Topics: Cyproheptadine; Humans; Muscle Spasticity; Neuromuscular Agents; Stroke; Stroke Rehabilitation; Surv | 2022 |
1 other study available for cyproheptadine and Stroke
| Article | Year |
|---|---|
Effect of a serotonin antagonist on delay in grip muscle relaxation for persons with chronic hemiparetic stroke.
Topics: Adult; Aged; Aged, 80 and over; Brain Stem; Cyproheptadine; Efferent Pathways; Electromyography; Fem | 2011 |